Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway

Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway

Hyperlipidaemia is one of the major risk factors for atherosclerosis, coronary heart disease, stroke and diabetes. In the present study, we synthesized a new anthraquinone compound, 1,8-dihydroxy-3-succinic acid monoethyl ester-6-methylanthraquinone, and named it Kanglexin (KLX). The aim of this stu...

Full description

Bibliographic Details
Main Authors: Xin Li, Xueling Hu, Tengfei Pan, Lei Dong, Lili Ding, Zhenzhong Wang, Rui Song, Xiuzhu Wang, Ning Wang, Yan Zhang, Jinhui Wang, Baofeng Yang
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Anthraquinone compound
Kanglexin
Hyperlipidaemia
Fatty liver
AMPK/SREBP-2/PCSK9/LDLR signalling pathway
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332220309951

Internet

http://www.sciencedirect.com/science/article/pii/S0753332220309951

Similar Items